Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-6222 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-6222 | EXPERIMENTAL | Participants will be administered a single dose of ALN-6222. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo. |
| Name | Type | Description |
|---|---|---|
| ALN-6222 | DRUG | ALN-6222 will be administered subcutaneously (SC). |
| Placebo | DRUG | Placebo will be administered SC. |
Inclusion Criteria - * Is an adult patient with a body mass index ≥30 kg/m\^2 to \<40 kg/m\^2 * Has a hemoglobin A1c \<6.5% Exclusion Criteria - * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>1.5 times the upper limit of normal (ULN) * Has known human immunodeficiency ...
Top 20 of 32 competitors
ALN-6222 is an investigational small molecule being developed for the treatment of obesity. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in a clinical trial enrolling participants with obesity.
ALN-6222 is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker ALNY. The company is conducting a Phase 1 clinical trial to evaluate the drug in participants with obesity.
ALN-6222 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is currently recruiting participants with obesity.
ALN-6222 is being evaluated in a Phase 1 clinical trial with the identifier NCT07624071, titled "A Study to Evaluate ALN-6222 in Participants With Obesity." The trial is recruiting 88 participants in Canada, is randomized, double-blind, and placebo-controlled.
Yes, ALN-6222 is a small molecule therapeutic. It is being developed as an oral or injectable treatment for obesity, though the specific route of administration has not been disclosed. The drug is currently in Phase 1 clinical testing.